Trials / Recruiting
RecruitingNCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 614 (estimated)
- Sponsor
- BeOne Medicines · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Detailed description
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Conditions
- B-cell Malignancy
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Non-Hodgkin Lymphoma
- Waldenström Macroglobulinemia
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-16673 | Orally administered |
Timeline
- Start date
- 2021-09-13
- Primary completion
- 2026-11-01
- Completion
- 2029-11-01
- First posted
- 2021-08-16
- Last updated
- 2026-04-15
Locations
126 sites across 16 countries: United States, Australia, Brazil, Canada, China, France, Georgia, Germany, Italy, Japan, Moldova, South Korea, Spain, Sweden, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05006716. Inclusion in this directory is not an endorsement.